# CRISM Therapeutics

Source: https://onco.cc/companies/crism-therapeutics/  
OnCo record `crism-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRISM Therapeutics makes ChemoSeed, small dissolving implants that release chemotherapy slowly into the tissue left behind after a brain tumour is removed. Its first trial is in people having surgery for glioblastoma in the UK.

## Summary

CRISM Therapeutics Corporation (AIM: CRTX) is a UK clinical-stage drug delivery company with a team based in Birmingham, a UK address in Londonderry and a registered office in Tortola, British Virgin Islands. Its ChemoSeed technology, developed by chief scientific officer Professor Chris McConville, is a cylinder of biodegradable polymer such as PLGA loaded with up to four chemotherapy drugs, implanted directly into a tumour or into the resection margin after surgery so that the drug diffuses into residual tumour tissue. The lead product, irinotecan-ChemoSeed, received MHRA approval and a favourable research ethics opinion in September 2025 for an open-label phase 2 trial in patients with surgically resectable glioblastoma at UK sites, planned to start in the first quarter of 2026. The company names pancreatic, prostate, bladder and breast cancers as possible future indications and also offers formulation services. Its first registered cancer trial, NCT07356973, was posted on ClinicalTrials.gov in January 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: CRISM Therapeutics Corporation
- HQ: Birmingham
- Type: biotech
- Website: https://www.crismtherapeutics.com/
- Ticker: AIM: CRTX

## Notes

- Not the same company as CRISPR Therapeutics, which has its own record.
- Founding year not stated on the company website.
- Preclinical mouse survival figures on the company website are not repeated here.
- Financing history was not read; the company's AIM admission document is listed on its investor pages but was not opened.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.crismtherapeutics.com/
- MHRA and ethics approval for the phase 2 glioblastoma trial, September 2025: https://www.crismtherapeutics.com/regulatory-and-ethical-approval-2/
- ChemoSeed technology: https://www.crismtherapeutics.com/chemoseed/
- ClinicalTrials.gov: phase 2 trial of irinotecan-ChemoSeed in resectable glioblastoma (NCT07356973): https://clinicaltrials.gov/study/NCT07356973

## Connected records

- companies: [CRISPR Therapeutics](https://onco.cc/companies/crispr-therapeutics/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Surgery & Interventional](https://onco.cc/fronts/surgery/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- trials: [Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma](https://onco.cc/trials/nct07356973/)

---
JSON: https://onco.cc/api/v1/entities/crism-therapeutics.json